215 related articles for article (PubMed ID: 21688986)
1. Liver toxicity of antiretroviral combinations including fosamprenavir plus ritonavir 1400/100 mg once daily in HIV/hepatitis C virus-coinfected patients.
Merchante N; López-Cortés LF; Delgado-Fernández M; Ríos-Villegas MJ; Márquez-Solero M; Merino D; Pasquau J; García-Figueras C; Martínez-Pérez MA; Omar M; Rivero A; Macías J; Mata R; Pineda JA;
AIDS Patient Care STDS; 2011 Jul; 25(7):395-402. PubMed ID: 21688986
[TBL] [Abstract][Full Text] [Related]
2. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Hicks CB; DeJesus E; Sloan LM; Sension MG; Wohl DA; Liao Q; Ross LL; Pakes GE; Pappa KA; Lancaster CT;
AIDS Res Hum Retroviruses; 2009 Apr; 25(4):395-403. PubMed ID: 19320570
[TBL] [Abstract][Full Text] [Related]
3. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study.
Gathe JC; Wood R; Sanne I; DeJesus E; Schürmann D; Gladysz A; Garris C; Givens N; Elston R; Yeo J
Clin Ther; 2006 May; 28(5):745-54. PubMed ID: 16861096
[TBL] [Abstract][Full Text] [Related]
4. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens.
Pineda JA; Pérez-Elías MJ; Peña JM; Luque I; Rodríguez-Alcantara F;
HIV Clin Trials; 2008; 9(5):309-13. PubMed ID: 18977719
[TBL] [Abstract][Full Text] [Related]
5. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
[TBL] [Abstract][Full Text] [Related]
6. Similar virologic and immunologic efficacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial.
Cohen C; Dejesus E; Lamarca A; Young B; Yau L; Patel L; Vavro C; Wire MB; Wannamaker P; Shaefer M
HIV Clin Trials; 2010; 11(5):239-47. PubMed ID: 21126954
[TBL] [Abstract][Full Text] [Related]
7. Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance.
Molina JM; Ait-Khaled M; Rinaldi R; Penco G; Baril JG; Cauda R; Soriano V; Pialoux G; Wire MB; Lou Y; Givens N; Craig C; Nichols WG; Barbosa I; Yeo J;
J Antimicrob Chemother; 2009 Aug; 64(2):398-410. PubMed ID: 19515730
[TBL] [Abstract][Full Text] [Related]
8. Fosamprenavir/ritonavir in patients with viral hepatitis coinfection: an observational multicohort study.
Nasta P; Salmon D; d'Arminio Monforte A; Pimenta JM; Cerini C; Giralda M; Winnock M; Cozzi-Lepri A
HIV Clin Trials; 2016 May; 17(3):96-108. PubMed ID: 27125364
[TBL] [Abstract][Full Text] [Related]
9. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety study of fosamprenavir-containing regimens in HIV-1-infected patients.
Wood R; Gathe JC; Givens N; Sedani S; Cheng K; Sievers J
HIV Clin Trials; 2013; 14(5):183-91. PubMed ID: 24144895
[TBL] [Abstract][Full Text] [Related]
11. Hepatic safety profile of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection.
Ha B; Wine B; Rodriguez-Alcantra F; Shaefer M
HIV Clin Trials; 2012; 13(3):171-7. PubMed ID: 22592097
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of once-daily fosamprenavir 1400 mg boosted by ritonavir 100 mg: the BOLD100 study.
Blick G; Greiger-Zanlungo P; Gretz S; Han J; Dupree D; Garton T; Yau LH; Wine BC; Pakes GE;
Int J STD AIDS; 2012 Mar; 23(3):e18-22. PubMed ID: 22581890
[TBL] [Abstract][Full Text] [Related]
13. SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients.
Gathe JC; Ive P; Wood R; Schürmann D; Bellos NC; DeJesus E; Gladysz A; Garris C; Yeo J
AIDS; 2004 Jul; 18(11):1529-37. PubMed ID: 15238771
[TBL] [Abstract][Full Text] [Related]
14. Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV-coinfected patients.
Macías J; Neukam K; Mallolas J; López-Cortés LF; Cartón JA; Domingo P; Moreno S; Iribarren JA; Clotet B; Crespo M; de Los Santos I; Ortega E; Knobel H; Jiménez-Expósito MJ; Pineda JA;
HIV Clin Trials; 2012; 13(2):61-9. PubMed ID: 22510353
[TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
Pulido F; Estrada V; Baril JG; Logue K; Schewe K; Plettenberg A; Duiculescu D; Yau L; Vavro C; Lim ML; Pharo C
HIV Clin Trials; 2009; 10(2):76-87. PubMed ID: 19487177
[TBL] [Abstract][Full Text] [Related]
16. Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.
Carosi ; Lazzarin ; Stellbrink ; Moyle ; Rugina ; Staszewski ; Givens ; Ross ; Granier ; Ait-Khaled ; Leather ; Nichols
HIV Clin Trials; 2009; 10(6):356-67. PubMed ID: 20133266
[TBL] [Abstract][Full Text] [Related]
17. Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients.
Lapadula G; Costarelli S; Chatenoud L; Castelli F; Astuti N; Di Giambenedetto S; Quiros-Roldan E; Sighinolfi L; Ladisa N; Di Pietro M; Zoncada A; Di Filippo E; Gori A; Nasta P; Torti C;
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):312-8. PubMed ID: 25723139
[TBL] [Abstract][Full Text] [Related]
18. Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.
Quercia R; Garnier E; Ferré V; Morineau P; Bonnet B; Soulard C; Raffi F
HIV Clin Trials; 2005; 6(2):73-80. PubMed ID: 15983891
[TBL] [Abstract][Full Text] [Related]
19. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Collier AC; Tierney C; Downey GF; Eshleman SH; Kashuba A; Klingman K; Vergis EN; Pakes GE; Rooney JF; Rinehart A; Mellors JW;
HIV Clin Trials; 2008; 9(2):91-102. PubMed ID: 18474494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
